 WESTLAKE VILLAGE, Calif., Oct. 29, 2020 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced it will present new data from the previously announced Phase 2 studies of ARQ-151 topical roflumilast cream in chronic plaque psoriasis and atopic dermatitis at the European Academy of Dermatology and Venereology EADV Virtual Congress EADV Virtual, the Society of Dermatology Physician Assistants SPDA Digital 2020 conference, and the virtual 2020 Fall Clinical Dermatology Conference. 